查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1308601

2030 年体外膜氧合器 (ECMO) 市场预测：按产品、组件、模式、患者类型、应用和地区进行的全球分析

Extracorporeal Membrane Oxygenation Machine Market Forecasts to 2030 - Global Analysis By Product, Component, Modality, Patient Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球体外膜肺氧合 (ECMO) 市场规模将达到 6.0837 亿美元，预测期内復合年增长率为 7.2%，预计到 2030 年2018年将达到9.8976亿美元。

体外膜肺氧合（ECMO）是一种生命支持技术，用于患有严重末期疾病的患者，这些疾病会损害心臟和肺部的正常功能并阻止他们正常呼吸。. 除了帮助等待心臟或肺移植的患者外，该机制还提供心肺旁路支持。 根据患者的情况，ECMO 支持可能是短期的，从几小时到几天，也可能持续数週。

根据体外生命支持机构的数据，2016 年 1 月，大约 8,102 名儿童患有心脏病，需要 ECMO 治疗。

市场动态：

驱动程序

肺移植中 ECMO 的使用增加

在预测期内，肺移植的需求不断增加，特别是用于治疗囊性纤维化、间质性肺病和慢性阻塞性肺病 (COPD) 等终末期肺病。 肺移植后原发性移植物功能障碍（PGD）是使用 ECMO 的最常见原因。 肺移植后 72 小时内发生的肺损伤称为 PGD 综合征。 由于技术的重大进步，ECMO 作为移植后 PGD 患者的过渡性治疗方式在各种研究中取得了有希望的结果。 由于全球肺部疾病患病率不断上升，ECMO 的使用预计将进一步增加。

限制

ECMO产品成本高

ECMO 是一种昂贵的医疗程序。 除了系统相关费用外，还有医院住宿和一次性配件等其他费用。 费用随使用时间的长短而变化，但由于需要更多的医务人员来照顾接受 ECMO 手术的患者，因此治疗费用会增加。 接受 ECMO 支持的患者的住院时间通常为一到两週，但根据患者病情的严重程度，住院时间可能会有所不同，甚至可能持续更长的时间。 因此，大多数患者无法承担该手术的总费用。

机会

ECMO 提高生存率

患有潜在可逆性呼吸衰竭的患者，例如严重急性呼吸窘迫综合征（ADRS）、肺移植后原发性移植物衰竭以及肺损伤，应接受VV-ECMO治疗。 接受VV-ECMO的呼吸衰竭患者存活率较高。 ECMO 设备也被应用于心臟，因为它们可以通过氧合支持功能失调的循环系统。 使用这些系统治疗心力衰竭的心脏病患者的生存率有所提高。

威胁

缺乏熟练的专业人员

ECMO 是一种高度专业化且复杂的治疗方法，需要对灌注师、重症监护师、护士和呼吸治疗师进行培训，使其具备有效操作和管理ECMO 设备的专业知识。需要一支训练有素的医疗专业人员团队。 然而，ECMO 疗法的广泛采用和使用受到具有 ECMO 特定知识和技能的训练有素的专业人员数量有限的挑战。 熟练的 ECMO 专业人员的短缺不仅影响了护理的提供，而且阻碍了 ECMO 项目的扩展和新的 ECMO 中心的建立。 如果没有足够数量的训练有素的专业人员，医疗机构可□□能不愿意投资 ECMO 设备或扩大 ECMO 服务，因为担心人手不足和患者护理下降。

COVID-19 的影响：

COVID-19 大流行深刻改变了全球医疗格局，导致 2020 年体外膜肺氧合 (ECMO) 市场显着高速增长。 这是由于病毒的广泛传播以及对这些机器提供循环支持和拯救生命的需求不断增长。 COVID-19 患者治疗效果的改善增加了医院对体外膜氧合 (ECMO) 的采用，从而刺激了对体外膜氧合 (ECMO) 的需求。 为了应对不断增长的需求，市场参与者在疫情期间见证了对其产品的需求增加。

预计泵领域在预测期内将是最大的领域：

由于其高成本和高使用率，泵领域也占有相当大的市场份额。 ECMO 机器的泵通过氧合器帮助患者的血液充氧，然后再返回患者体内。 泵在ECMO治疗中的广泛使用以及多种类型泵（例如滚子泵、叶轮泵和离心泵）的出现极大地扩展了这一领域。 这些泵根据其要求用于各种 ECMO 程序，预计将在预测期内刺激该领域的市场扩张。

在预测期内，呼吸领域的复合年增长率最高：

在预测期内，呼吸领域将见证最高的市场复合年增长率。 由于目标疾病的快速传播、早期诊断和医学检测的有限性以及体外膜肺氧合器市场的技术发展，该市场正在不断扩大。 由于结核病、胸部恶性肿瘤、骨质疏鬆症、骨折和心血管疾病危险因素等呼吸系统疾病患病率的上升，诊断医学成像也在不断扩大，这将推动该领域的增长。

市场份额最高的地区：

北美在预测期内主导市场。 北美是体外膜肺氧合（ECMO）的重要市场，该地区有多家领先公司。 该地区市场的增长归因于政府对优质医疗保健的支持、高购买力平价以及美国和加拿大慢性阻塞性肺病等疾病患病率的上升。 先进的医疗设施和优惠的报销政策预计将增加住院人数，从而提高该地区的利用率。

复合年增长率最高的地区：

亚太市场预计在预测期内将以最快的速度增长。 老年人口的增加、可支配收入的增加、更先进技术的价格下降、目标疾病患病率的上升以及政府的支持措施（尤其是在日本）是亚太地区 ECMO 设备市场增长的主要推动力。 这些因素推动了该地区数字成像设备市场的发展，吸引了国外的合作和投资。 另一方面，亚太地区的市场扩张在一定程度上受到医院预算低、设备成本高以及一些国家政府支出不足的限制。

主要进展：

  • 2022 年 5 月，微创科学公司收购 Hemovent GmbH，Hemovent GmbH 的 MOBYBOX ECMO 系统用于治疗 COVID-19 患者，发表在领先的国际医学期刊 - ASAIO Journal
  • 2022 年 11 月，LivaNova PLC 宣布 LifeSPARC 获得 FDA 批准；
  • 2021年10月，微创医疗收购德国ECLS公司Hemovent GmbH，投资拓展德国业务
  • 2021 年 7 月，Xenios AG 的 Xenios 控制台和用于 ECMO 治疗的患者套件获得中国国家药品监督管理局 (NMPA) 的批准

报告内容

  • 区域和国家层面的市场细分
  • 给新进入者的战略建议
  • 涵盖 2021 年、2022 年、2023 年、2026 年和 2030 年的市场数据
  • 市场趋势
  • 根据市场预测提出关键业务领域的战略建议
  • 竞争格局绘製主要共同趋势
  • 公司简介，包括详细的战略、财务状况和最新发展
  • 供应链趋势映射最新技术趋势

免费定制服务：

订阅此报告的客户将获得以下免费自定义选项之一：

  • 公司简介
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要公司的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家/地区的市场估计/预测/复合年增长率（注：基于可行性检查）
  • 竞争基准测试
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 执行摘要
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究来源
    • 二手研究来源
    • 先决条件

第三章市场趋势分析

  • 驱动程序
  • 制约因素
  • 机会
  • 威胁
  • 产品分析
  • 使用情况分析
  • 新兴市场
  • 新冠肺炎 (COVID-19) 的影响

第 4 章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间存在敌对关係

第五章全球体外膜氧合器 (ECMO) 市场：按产品

  • 便携式设备
  • 固定设备
  • 软件
  • 其他产品

第 6 章全球体外膜氧合 (ECMO) 市场：按组成部分

  • 泵
  • 制氧机
  • 控制器
  • 插管
  • 呼吸配件
  • 其他组件

第 7 章：全球体外膜氧合 (ECMO) 市场：按模式

  • 静脉 - 静脉
  • 静脉-动脉
  • 动静脉
  • 其他方式

第 8 章全球体外膜氧合 (ECMO) 市场：按患者类型划分

  • 新生儿
  • 儿科
  • 成人

第 9 章全球体外膜氧合 (ECMO) 市场：按应用分类

  • 呼吸系统
  • 心
  • 体外心肺復苏 (ECPR)
  • 心肺復苏 (CPR)
  • 先天性心脏病
  • 桥接端口
  • 其他用途

第 10 章全球体外膜氧合 (ECMO) 市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东/非洲

第 11 章主要进展

  • 合同、合作伙伴关係、联盟和合资企业
  • 收购与合併
  • 推出新产品
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • ABIOMED
  • EUROSETS
  • Getinge AB
  • LivaNova PLC
  • MAQUET Holding B.V. & Co. KG
  • Medos Medizintechnik AG
  • Medtronic
  • Microport Scientific Corporation
  • Nipro Medical Corporation
  • Sorin Group
  • Spectrum Medical
  • Terumo Cardiovascular Systems Corporation
  • Xenios AG
Product Code: SMRC23316

According to Stratistics MRC, the Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market is accounted for $608.37 million in 2023 and is expected to reach $989.76 million by 2030 growing at a CAGR of 7.2% during the forecast period. Extracorporeal membrane oxygenation is a type of life-supporting technology used for individuals with severe, terminal illnesses that impair their heart's or lungs' ability to function normally and keep them from breathing normally. In addition to helping those awaiting a heart or lung transplant, this mechanism offers heart-lung bypass support. Depending on the patient's medical state, ECMO machine support may be given for a short period of time-a few hours or days-or it may last for a few weeks.

According to the Extracorporeal Life Support Organization, in January 2016, around 8,102 children suffered from cardiac illness and required ECMO therapy.

Market Dynamics:

Driver:

Increasing use of ECMO in lung transplant procedures

The need for lung transplants has grown over the forecast period, particularly for the treatment of terminal lung conditions such as cystic fibrosis, Interstitial Lung Disease, and Chronic Obstructive Pulmonary Disease (COPD). Primary Graft Dysfunction (PGD) after lung transplantation is the most frequent cause for the use of ECMO. Lung damage that occurs within the first 72 hours after a lung transplant is known as PGD syndrome. The use of ECMO as a bridging method as a treatment for patients with PGD post-transplant has produced promising results in various studies thanks to considerable technological advancements. The use of ECMO is anticipated to increase further due to the rising prevalence of lung disorders worldwide.

Restraint:

High cost of ECMO products

ECMO is an expensive medical procedure. In addition to the expenditures related to the systems, there are other charges such as hospital lodging and extra disposable accessories. The cost of the treatment increases with the need for a large medical staff to care for the patient receiving an ECMO procedure, although the cost varies depending on how long it is used. The typical hospital stay for a patient receiving ECMO support is between one and two weeks, though it might vary depending on how serious the patient's condition is and last longer. The majority of patients cannot afford the procedure's higher overall cost as a result.

Opportunity:

Increasing survival rates with ECMO

Patients with potentially reversible respiratory failure, such as those with severe acute respiratory distress syndrome (ADRS), primary graft dysfunction following lung transplantation, and lung injury, should be treated with VV-ECMO. Patients with respiratory failure who receive VV-ECMO have a higher survival rate. Due to their capability to support failing circulatory systems with oxygenation functions, ECMO machines are also used in cardiac applications. The survival rates of cardiac patients who use these systems for heart failure are increased.

Threat:

Lack of skilled professionals

ECMO is a highly specialized and complex therapy that requires a team of trained healthcare professionals, including perfusionists, intensivists, nurses, and respiratory therapists, who possess the expertise to operate and manage ECMO machines effectively. However, the limited availability of trained professionals with ECMO-specific knowledge and skills poses challenges to the broader adoption and utilization of ECMO therapy. The lack of skilled professionals in ECMO not only affects the delivery of therapy but also impedes the expansion of ECMO programs and the establishment of new ECMO centers. Without a sufficient number of trained professionals, healthcare facilities may be hesitant to invest in ECMO machines or expand their ECMO services, fearing inadequate staffing and compromised patient care.

COVID-19 Impact::

The COVID-19 pandemic has significantly changed the landscape of healthcare practices worldwide and resulted in considerably high growth of the extracorporeal membrane oxygenation machine market in 2020. This is attributed to the vast spread of the virus and the increasing need for these machines to provide circulatory support and save lives. The improved machine outcome in COVID-19 patients led to increased adoption of these machines in hospitals, thereby fueling the demand for extracorporeal membrane oxygenation machines. Owing to the rise in demand, market players witnessed increased demand for their products during the pandemic.

The pumps segment is expected to be the largest during the forecast period:

The pumps segment also has a considerable market share owing to its high cost and usage. The ECMO machines' pumps assist in moving a patient's blood through artificial lungs for oxygenation before returning the blood to the patient. Due to the widespread use of pumps in ECMO treatments and the accessibility of many types of pumps, including roller, impeller, and centrifugal pumps, the segment has experienced significant expansion. According to their requirements, these pumps are employed in a variety of ECMO procedures, which will fuel the market expansion of this sector throughout the forecasted time.

The respiratory segment is expected to have the highest CAGR during the forecast period:

The respiratory segment has the highest CAGR in the market over the forecast period. The market is expanding due to the rapid spread of the target diseases, the limited availability of early diagnosis and medical testing, and technological developments in the Extracorporeal Membrane Oxygenation Machine Market. Diagnostic medical imaging is also expanding due to the rising incidence of respiratory diseases like tuberculosis, thorax malignant neoplasms, osteoporosis, broken bones, and CVD risk factors, which will propel the segment's growth.

Region with highest share:

North America dominated the market over the forecast period. North America is a significant market for Extracorporeal Membrane Oxygenation (ECMO) Machines, with several prominent players operating in the region. The growth of this market in the region can be attributed to the government support for quality healthcare, high purchasing power parity, and the increasing prevalence of diseases such as chronic obstructive pulmonary disease in the U.S. and Canada. The presence of sophisticated healthcare facilities and favorable reimbursement policies has led to an increased hospital admission rate which in turn is expected to boost the usage rates in this region.

Region with highest CAGR:

During the forecast period, the Asia Pacific market is anticipated to grow at the fastest rate. The rising geriatric population, especially in Japan, rising disposable incomes, making more advanced technologies affordable, the rising prevalence of target diseases, and supportive government initiatives are the main drivers of the ECMO machine market's growth in the Asia Pacific region. These elements propel the regional market for digital imaging equipment and draw in collaborations and investments from abroad. On the other hand, the expansion of the market in the Asia Pacific is being somewhat constrained by low hospital budgets, expensive equipment costs, and a lack of government expenditures in some nations.

Key players in the market

Some of the key players in Extracorporeal Membrane Oxygenation (ECMO) Machine Market include ABIOMED, EUROSETS, Getinge AB, LivaNova PLC, MAQUET Holding B.V. & Co. KG, Medos Medizintechnik AG, Medtronic, Microport Scientific Corporation, Nipro Medical Corporation, Sorin Group, Spectrum Medical, Terumo Cardiovascular Systems Corporation and Xenios AG.

Key Developments:

  • In May 2022, MicroPort Scientific Corporation acquired Hemovent GmbH and Hemovent GmbH's MOBYBOX ECMO System for the Treatment of COVID-19 Patients Published in Leading International Medical Journal-ASAIO Journal
  • In November 2022, LivaNova PLC announced the FDA clearance for LifeSPARC. The company received 510(k) approval for its next-generation advanced circulatory support system
  • In October 2021, MicroPort Scientific Corporation acquired German Extracorporeal life support (ECLS) company Hemovent GmbH and invested in expanding the company's German operations
  • In July 2021, Xenios AG received approval from the National Medical Products Administration (NMPA) in China for the Xenios Console and patient kits for ECMO therapy

Products Covered:

  • Portable Devices
  • Static Devices
  • Software
  • Other Products

Components Covered:

  • Pumps
  • Oxygenators
  • Controllers
  • Cannul a
  • Breathing Accessories
  • Other Components

Modalities Covered:

  • Veno-Venous
  • Veno-Arterials
  • Arterio-Venous
  • Other Modalities

Patient Types Covered:

  • Neonates
  • Pediatrics
  • Adults

Applications Covered:

  • Respiratory
  • Cardiac
  • Extracorporeal Cardiopulmonary Resuscitation (ECPR)
  • Cardiopulmonary Resuscitation (CPR)
  • Congenital Heart Defects
  • Bridge to Transplantation
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026 and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Product

  • 5.1 Introduction
  • 5.2 Portable Devices
  • 5.3 Static Devices
  • 5.4 Software
  • 5.5 Other Products

6 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Component

  • 6.1 Introduction
  • 6.2 Pumps
  • 6.3 Oxygenators
  • 6.4 Controllers
  • 6.5 Cannula
  • 6.6 Breathing Accessories
  • 6.7 Other Components

7 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Modality

  • 7.1 Introduction
  • 7.2 Veno-Venous
  • 7.3 Veno-Arterials
  • 7.4 Arterio-Venous
  • 7.5 Other Modalities

8 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Patient Type

  • 8.1 Introduction
  • 8.2 Neonates
  • 8.3 Pediatrics
  • 8.4 Adults

9 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Application

  • 9.1 Introduction
  • 9.2 Respiratory
  • 9.3 Cardiac
  • 9.4 Extracorporeal cardiopulmonary resuscitation (ECPR)
  • 9.5 Cardiopulmonary Resuscitation (CPR)
  • 9.6 Congenital Heart Defects
  • 9.7 Bridge to Transplantation
  • 9.8 Other Applications

10 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 ABIOMED
  • 12.2 EUROSETS
  • 12.3 Getinge AB
  • 12.4 LivaNova PLC
  • 12.5 MAQUET Holding B.V. & Co. KG
  • 12.6 Medos Medizintechnik AG
  • 12.7 Medtronic
  • 12.8 Microport Scientific Corporation
  • 12.9 Nipro Medical Corporation
  • 12.10 Sorin Group
  • 12.11 Spectrum Medical
  • 12.12 Terumo Cardiovascular Systems Corporation
  • 12.13 Xenios AG

List of Tables

  • Table 1 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Portable Devices (2021-2030) ($MN)
  • Table 4 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Static Devices (2021-2030) ($MN)
  • Table 5 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Software (2021-2030) ($MN)
  • Table 6 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Component (2021-2030) ($MN)
  • Table 8 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Pumps (2021-2030) ($MN)
  • Table 9 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Oxygenators (2021-2030) ($MN)
  • Table 10 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Controllers (2021-2030) ($MN)
  • Table 11 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Cannula (2021-2030) ($MN)
  • Table 12 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Breathing Accessories (2021-2030) ($MN)
  • Table 13 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Other Components (2021-2030) ($MN)
  • Table 14 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Modality (2021-2030) ($MN)
  • Table 15 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Veno-Venous (2021-2030) ($MN)
  • Table 16 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Veno-Arterials (2021-2030) ($MN)
  • Table 17 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Arterio-Venous (2021-2030) ($MN)
  • Table 18 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Other Modalities (2021-2030) ($MN)
  • Table 19 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Patient Type (2021-2030) ($MN)
  • Table 20 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Neonates (2021-2030) ($MN)
  • Table 21 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Pediatrics (2021-2030) ($MN)
  • Table 22 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Adults (2021-2030) ($MN)
  • Table 23 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Respiratory (2021-2030) ($MN)
  • Table 25 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Cardiac (2021-2030) ($MN)
  • Table 26 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Extracorporeal cardiopulmonary resuscitation (ECPR) (2021-2030) ($MN)
  • Table 27 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Cardiopulmonary Resuscitation (CPR) (2021-2030) ($MN)
  • Table 28 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Congenital Heart Defects (2021-2030) ($MN)
  • Table 29 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Bridge to Transplantation (2021-2030) ($MN)
  • Table 30 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.